Clinical Insights on R/R Follicular Lymphoma: ASH 2024 Highlights

Panelists discuss how the BRAF-KIAA-1549 fusion impacts treatment decisions in cancers like such as low-grade gliomas, emphasizing the role of targeted therapies and the importance of molecular testing for optimal patient disease management.

EP. 1: Treatment Strategies in 2L R/R FL: When to Treat vs Observe in Relapsed Disease

December 23rd 2024

Panelists discuss how the treatment approach for relapsed or progressive follicular lymphoma (R/R FL) in the second-line (2L) setting is evolving, focusing on the role of observation vs intervention and the potential impact of ASH 2024 updates, including the inMIND study with tafasitamab and the EPCORE NHL-2 trial with epcoritamab + R2.

EP. 2: Clinical Perspectives Selecting 2L Treatment Options in R/R FL: Chemoimmunotherapy vs Lenalidomide Combinations in Relapsed Disease

January 4th 2025

Panelists discuss how their treatment approaches in the second-line (2L) setting for relapsed or progressive follicular lymphoma (R/R FL) are influenced by factors such as the duration of response to first-line therapy, tumor burden, and symptomatology, while also exploring the use of chemoimmunotherapy, lenalidomide combinations, and anti-CD20 monotherapy in clinical decision-making.

EP. 3: ASH 2024 Updates: inMIND study With Tafasitamab Combined With Lenalidomide and Rituximab in R/R FL

January 11th 2025

Panelists discuss the key findings from the ASH 2024 late-breaking presentation on the inMIND study, highlighting the superior efficacy and safety of tafasitamab combined with lenalidomide and rituximab over the current standard of care, and how these results may impact treatment strategies in the second-line (2L) setting for relapsed/refractory follicular lymphoma, if approved.

EP. 4: Expert Insights: How Tafasitamab + R2 May Impact Clinical Practice in R/R FL

January 11th 2025

Panelists discuss the potential impact of tafasitamab + R2 on clinical practice in relapsed/refractory follicular lymphoma, including initial thoughts on the combination of CD19 and CD20 in a phase 3 trial, identification of ideal patient candidates, and potential challenges or toxicity risks associated with this triplet regimen.

EP. 5: Exploring Tafasitamab in 2L Treatment: Challenges, Impact on Decision-Making, and Key Insights From inMIND Study

January 18th 2025

Panelists discuss how the approval of tafasitamab + lenalidomide and rituximab (R2) in the second-line (2L) setting might influence decision-making in the first-line (1L) or third line–plus (3L+) treatment settings and share their thoughts on the inMIND study, highlighting key data points and the impact of tafasitamab + R2 on clinical practice.

EP. 6: ASH 2024 Updates: EPCORE NHL-2 Trial With Fixed-Duration Epcoritamab + R2

January 18th 2025

Panelists discuss the 2-year follow-up data from the EPCORE NHL-2 trial with fixed-duration epcoritamab + lenalidomide and rituximab (R2) presented at the American Society of Hematology (ASH), and how the potential move of epcoritamab from the third-line (3L) to the second-line (2L) setting might impact treatment approaches.

EP. 7: Differentiating Treatment Options: Epcoritamab + R2 vs Tafasitamab-Lenalidomide-Rituximab in R/R FL

January 25th 2025

Panelists discuss how they anticipate differentiating candidates for epcoritamab + lenalidomide and rituximab (R2) vs those better suited for tafasitamab-lenalidomide-rituximab, considering the factors that most influence their decisions, and share their impressions of the EPCORE NHL-2 trial, including potential treatment sequencing implications between the 2 regimens.

EP. 8: Choosing Bispecifics in 3L Treatment Setting R/R FL

January 25th 2025

Panelists discuss the use of bispecifics in the third-line setting for relapsed/refractory follicular lymphoma (R/R FL), exploring how often they are utilized and how bispecifics fit into the treatment paradigm compared with other options like chimeric antigen receptor (CAR) T, EZH2 inhibitors, and Bruton tyrosine kinase (BTK) inhibitors.

EP. 9: ASH 2024 CAR T and Bispecifics Updates: Key Insights and Practical Considerations in 3L R/R FL Treatment

February 1st 2025

Panelists discuss key highlights from American Society of Hematology (ASH) 2024 updates on long-term follow-ups across chimeric antigen receptor (CAR) T trials and a matching-adjusted indirect comparison (MAIC) of outcomes with liso-cel, axi-cel, and tisa-cel, sharing their impressions of the MAIC data and their influence on day-to-day decision-making.

EP. 10: Navigating the Evolving Treatment Landscape in R/R FL: When to Consider BTK and EZH2 Inhibitors

February 1st 2025

Panelists discuss how they collaborate with community sites for chimeric antigen receptor (CAR) T and bispecifics administration, accessibility, and monitoring, and explore the factors influencing the use of tazemetostat or zanubrutinib + obinutuzumab, including patient selection, accessibility, and sequencing in relation to CAR T or bispecific therapies.

EP. 11: Expert Perspectives: Sequencing Tafasitamab + R2 With Currently Available Options in 3L Setting

February 8th 2025

Panelists discuss potential clinical scenarios where tafasitamab + lenalidomide + rituximab might be considered after chimeric antigen receptor (CAR) T, bispecifics, tazemetostat, or zanubrutinib in the treatment of relapsed/refractory lymphoma.

EP. 12: Reflecting on 2024: Key Achievements and Looking Ahead to 2025 in R/R FL Treatment

February 8th 2025

Panelists share their final thoughts on the advancements made in 2024, including exciting data from American Society of Hematology (ASH) 2024, and reflect on key accomplishments in relapsed/refractory follicular lymphoma (R/R FL) that have shaped clinical practice. They also discuss what they are most excited about in 2025, areas primed for significant progress, and goals for the coming year.

x